Skip to main content
Top
Published in: Journal of Gastroenterology 2/2015

01-02-2015 | Review

Diagnostic strategies for early pancreatic cancer

Authors: Keiji Hanada, Akihito Okazaki, Naomichi Hirano, Yoshihiro Izumi, Yuji Teraoka, Juri Ikemoto, Kozue Kanemitsu, Fumiaki Hino, Toshikatsu Fukuda, Shuji Yonehara

Published in: Journal of Gastroenterology | Issue 2/2015

Login to get access

Abstract

Diagnosis of pancreatic cancer (PC) at an early stage with curative surgery is the approach with the potential to significantly improve long-term patient outcome. Recently, some reports showed that patients with pancreatic tumors smaller than 10 mm showed a favorable prognosis. However, the rate of tumor detection on computed tomography in patients with small pancreatic tumors is low. For the diagnoses of PC with tumors smaller than 10 mm, the rate of tumor detection was higher on endoscopic ultrasonography (EUS) than on computed tomography or other modalities, and histologic diagnosis using EUS-guided fine-needle aspiration was helpful in confirming the diagnosis. For the diagnosis of PC in situ, EUS and magnetic resonance cholangiopancreatography may play important roles in detecting the local irregular stenosis of the pancreatic duct. Endoscopic retrograde pancreatography and sequential cytodiagnosis using pancreatic juice obtained by endoscopic nasopancreatic drainage multiple times was useful in the final diagnosis of PC in situ. At present, improving survival lies in identifying those individuals with high-risk factors or precursor lesions through an effective screening method. For example, these should include ultrasonography, various biological markers, or national familial pancreatic cancer registration. Additionally, the relationship between specialists in PC from medical centers and practicing physicians plays an important role in the early diagnosis of PC.
Literature
2.
4.
go back to reference Furuta K, Watanabe H, Ikeda S. Differences between solid and duct-ectatic type of pancreatic ductal carcinoma. Cancer. 1992;69:1327–33.PubMedCrossRef Furuta K, Watanabe H, Ikeda S. Differences between solid and duct-ectatic type of pancreatic ductal carcinoma. Cancer. 1992;69:1327–33.PubMedCrossRef
5.
go back to reference Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary. Pancreas. 2012;41:985–92.PubMedCrossRef Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary. Pancreas. 2012;41:985–92.PubMedCrossRef
6.
go back to reference Yamaguchi K, Okusaka T, Shimizu K, et al. EBM-based clinical guidelines for pancreatic cancer (2013) issued by the Japan Pancreatic Society: a synopsis. Jpn J Clin Oncol. 2014. doi:10.1093/jjco/hyu127. Yamaguchi K, Okusaka T, Shimizu K, et al. EBM-based clinical guidelines for pancreatic cancer (2013) issued by the Japan Pancreatic Society: a synopsis. Jpn J Clin Oncol. 2014. doi:10.​1093/​jjco/​hyu127.
7.
go back to reference Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008;57:1561–5.PubMedCrossRef Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008;57:1561–5.PubMedCrossRef
8.
go back to reference Hanada K, Amano H, Hino F, et al. Management strategies for branch duct intraductal papillary-mucinous neoplasms. Dig Endosc. 2006;18:S68–72.CrossRef Hanada K, Amano H, Hino F, et al. Management strategies for branch duct intraductal papillary-mucinous neoplasms. Dig Endosc. 2006;18:S68–72.CrossRef
9.
go back to reference Tada M, Kawase T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265–70.PubMedCrossRef Tada M, Kawase T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265–70.PubMedCrossRef
10.
go back to reference Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011;40:364–70.PubMedCrossRef Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011;40:364–70.PubMedCrossRef
11.
go back to reference Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40:571–80.PubMedCrossRef Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40:571–80.PubMedCrossRef
12.
go back to reference Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev. 2013;13:66–74.CrossRef Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev. 2013;13:66–74.CrossRef
13.
go back to reference Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasma in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–21.PubMedCrossRef Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasma in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–21.PubMedCrossRef
14.
go back to reference Hruban RH, Petersen GM, Goggins M, et al. Familiar pancreatic cancer. Ann Oncol. 1999;10(Suppl 4):69–73.PubMedCrossRef Hruban RH, Petersen GM, Goggins M, et al. Familiar pancreatic cancer. Ann Oncol. 1999;10(Suppl 4):69–73.PubMedCrossRef
16.
go back to reference Vesen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familiar atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16 Leiden). Int J Cancer. 2000;87:809–11.CrossRef Vesen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familiar atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16 Leiden). Int J Cancer. 2000;87:809–11.CrossRef
17.
go back to reference Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenteol. 2009;104:2175–81.CrossRef Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenteol. 2009;104:2175–81.CrossRef
18.
go back to reference Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2011;140:850–6.PubMedCrossRef Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2011;140:850–6.PubMedCrossRef
19.
go back to reference Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol. 1997;6:157–69.PubMedCrossRef Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol. 1997;6:157–69.PubMedCrossRef
20.
go back to reference Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA19–9 in the diagnosis, prognosis and management of pancreatic adenocarcimona: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105–19.PubMedCentralPubMed Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA19–9 in the diagnosis, prognosis and management of pancreatic adenocarcimona: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105–19.PubMedCentralPubMed
21.
go back to reference Nishiumi S, Shinohara M, Ikeda A, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518–28.CrossRef Nishiumi S, Shinohara M, Ikeda A, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518–28.CrossRef
22.
go back to reference Kobayashi T, Nishiumi S, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22:571–9.CrossRef Kobayashi T, Nishiumi S, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22:571–9.CrossRef
24.
go back to reference Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007;67:4553–5.PubMedCrossRef Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007;67:4553–5.PubMedCrossRef
25.
go back to reference Mori Y, Ohtsuka T, Kono H, et al. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Pancreas. 2013;42:187–92.PubMedCrossRef Mori Y, Ohtsuka T, Kono H, et al. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Pancreas. 2013;42:187–92.PubMedCrossRef
26.
go back to reference Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81.PubMedCrossRef Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81.PubMedCrossRef
27.
go back to reference Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804.PubMedCentralPubMedCrossRef Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804.PubMedCentralPubMedCrossRef
28.
go back to reference Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familiar pancreatic cancer. Gut. 2013;62:339–47.PubMedCentralPubMedCrossRef Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familiar pancreatic cancer. Gut. 2013;62:339–47.PubMedCentralPubMedCrossRef
29.
go back to reference Kamata K, Kitano M, Kudo S, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2014;46:22–9.PubMedCrossRef Kamata K, Kitano M, Kudo S, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2014;46:22–9.PubMedCrossRef
30.
go back to reference Tanaka S, Nakao M, Ioka T, et al. Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer: a prospective study. Radiology. 2010;254:965–72.PubMedCrossRef Tanaka S, Nakao M, Ioka T, et al. Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer: a prospective study. Radiology. 2010;254:965–72.PubMedCrossRef
31.
go back to reference Hanada K, Iiboshi T, Hirano N, et al. Role of EUS for small pancreatic cancer less than 1 cm. Tan Sui. 2009;30:343–8 (In Japanese). Hanada K, Iiboshi T, Hirano N, et al. Role of EUS for small pancreatic cancer less than 1 cm. Tan Sui. 2009;30:343–8 (In Japanese).
32.
go back to reference Sakamoto H, Kitano M, Takeyama Y, et al. Early diagnosis of pancreatic cancer: approach to the diagnosis of very small pancreatic cancer with emphasis of US, MDCT and EUS. Tan Sui. 2009;30:335–41 (In Japanese). Sakamoto H, Kitano M, Takeyama Y, et al. Early diagnosis of pancreatic cancer: approach to the diagnosis of very small pancreatic cancer with emphasis of US, MDCT and EUS. Tan Sui. 2009;30:335–41 (In Japanese).
33.
go back to reference Takeshita K, Kutomi K, Haruyama T, et al. Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol. 2010;83:823–30.PubMedCentralPubMedCrossRef Takeshita K, Kutomi K, Haruyama T, et al. Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol. 2010;83:823–30.PubMedCentralPubMedCrossRef
34.
go back to reference Hijioka S, Ikari T, Kamei A, et al. CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase. Hepatogastroenterology. 2007;54:389–92.PubMed Hijioka S, Ikari T, Kamei A, et al. CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase. Hepatogastroenterology. 2007;54:389–92.PubMed
35.
go back to reference Serrano OK, Chaudhry MA, Leach SD, et al. The role of PET scanning in pancreatic cancer. Adv Surg. 2010;44:313–25.PubMedCrossRef Serrano OK, Chaudhry MA, Leach SD, et al. The role of PET scanning in pancreatic cancer. Adv Surg. 2010;44:313–25.PubMedCrossRef
36.
go back to reference Okano K, Kakinoki K, Akamoto S, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol. 2011;17:231–5.PubMedCentralPubMedCrossRef Okano K, Kakinoki K, Akamoto S, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol. 2011;17:231–5.PubMedCentralPubMedCrossRef
37.
go back to reference Seo S, Doi R, Machimoto T, et al. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:634–9.PubMedCrossRef Seo S, Doi R, Machimoto T, et al. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:634–9.PubMedCrossRef
38.
go back to reference Matsumoto I, Shirakawa S, Shinzeki M, et al. 18F-fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:712–8.PubMedCrossRef Matsumoto I, Shirakawa S, Shinzeki M, et al. 18F-fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:712–8.PubMedCrossRef
39.
go back to reference Maguchi H. The roles of endoscopic ultrasonography in the diagnosis of pancreatic tumors. J Hepatobilbiliary Pancreat Surg. 2004;11:1–3.CrossRef Maguchi H. The roles of endoscopic ultrasonography in the diagnosis of pancreatic tumors. J Hepatobilbiliary Pancreat Surg. 2004;11:1–3.CrossRef
40.
go back to reference Irisawa A, Sato A, Ikeda T, et al. Early diagnosis of small pancreatic cancer: role of endoscopic ultrasonography. Dig Endosc. 2009;21:S92–6.PubMedCrossRef Irisawa A, Sato A, Ikeda T, et al. Early diagnosis of small pancreatic cancer: role of endoscopic ultrasonography. Dig Endosc. 2009;21:S92–6.PubMedCrossRef
41.
go back to reference Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56:S82–6.PubMedCrossRef Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56:S82–6.PubMedCrossRef
42.
go back to reference Geenhalf W, Neoptolemos JP. Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol. 2006;3:346–7.CrossRef Geenhalf W, Neoptolemos JP. Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol. 2006;3:346–7.CrossRef
43.
go back to reference Yasuda I, Iwashita T, Doi S, et al. Role of EUS in the early detection of small pancreatic cancer. Dig Endosc. 2011;23(Suppl 1):22–5.PubMedCrossRef Yasuda I, Iwashita T, Doi S, et al. Role of EUS in the early detection of small pancreatic cancer. Dig Endosc. 2011;23(Suppl 1):22–5.PubMedCrossRef
44.
go back to reference Uehara H, Ikezawa K, Kawada N, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic malignancy in relation to the size of lesions. J Gastroenterol Hepatol. 2011;26:1256–61.PubMedCrossRef Uehara H, Ikezawa K, Kawada N, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic malignancy in relation to the size of lesions. J Gastroenterol Hepatol. 2011;26:1256–61.PubMedCrossRef
45.
go back to reference Takagi T, Irisawa A, Sawaki A, et al. Effectiveness of EUS-FNA for the diagnosis of small pancreatic cancer less than 10 mm. Tan Sui. 2009;30:361–7 (In Japanese). Takagi T, Irisawa A, Sawaki A, et al. Effectiveness of EUS-FNA for the diagnosis of small pancreatic cancer less than 10 mm. Tan Sui. 2009;30:361–7 (In Japanese).
46.
go back to reference Yokohata K, Shirahane H, Yonemasu T, et al. Focal ductal branch on magnetic resonance cholangiopancreatography: a hint for early diagnosis of pancreatic carcinoma. Scand J Gastroenterol. 2000;11:1229–32. Yokohata K, Shirahane H, Yonemasu T, et al. Focal ductal branch on magnetic resonance cholangiopancreatography: a hint for early diagnosis of pancreatic carcinoma. Scand J Gastroenterol. 2000;11:1229–32.
47.
go back to reference Hanada K, Iiboshi T, Yamao K, et al. Diagnostic strategies for the early diagnosis of pancreatic cancer. Gastroenterol Endosc. 2012;54:3773–82 (In Japanese with English abstract). Hanada K, Iiboshi T, Yamao K, et al. Diagnostic strategies for the early diagnosis of pancreatic cancer. Gastroenterol Endosc. 2012;54:3773–82 (In Japanese with English abstract).
48.
go back to reference Seki M, Ninomiya E, Takano K, et al. Pancreatogram findings for carcinoma in situ (CIS) of the pancreas seen on endoscopic retrograde cholangiopancreatography and postoperative pancreatography of resected specimens: can CIS be diagnosed preoperatively? Pancreatology. 2008;8:142–52.PubMedCrossRef Seki M, Ninomiya E, Takano K, et al. Pancreatogram findings for carcinoma in situ (CIS) of the pancreas seen on endoscopic retrograde cholangiopancreatography and postoperative pancreatography of resected specimens: can CIS be diagnosed preoperatively? Pancreatology. 2008;8:142–52.PubMedCrossRef
49.
go back to reference Ikeda S, Maeshiro K, Ryu S, et al. Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography. Pancreas. 2009;38:e102–13.PubMedCrossRef Ikeda S, Maeshiro K, Ryu S, et al. Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography. Pancreas. 2009;38:e102–13.PubMedCrossRef
50.
go back to reference Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–76.PubMedCentralPubMed Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–76.PubMedCentralPubMed
51.
go back to reference Iiboshi T, Hanada K, Fukuda T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer. Pancreas. 2012;41:523–9.PubMedCrossRef Iiboshi T, Hanada K, Fukuda T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer. Pancreas. 2012;41:523–9.PubMedCrossRef
52.
go back to reference Takaori K, Matsusue S, Fujikawa T, et al. Carcinoma in situ of the pancreas associated with localized fibrosis: a clue to early detection of neoplastic lesions arising from pancreatic ducts. Pancreas. 1998;17:102–5.PubMedCrossRef Takaori K, Matsusue S, Fujikawa T, et al. Carcinoma in situ of the pancreas associated with localized fibrosis: a clue to early detection of neoplastic lesions arising from pancreatic ducts. Pancreas. 1998;17:102–5.PubMedCrossRef
53.
go back to reference Nakaizumi A, Tatsuta M, Uehara H, et al. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique. Cancer. 1992;70:2610–4.PubMedCrossRef Nakaizumi A, Tatsuta M, Uehara H, et al. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique. Cancer. 1992;70:2610–4.PubMedCrossRef
54.
go back to reference Nakaizumi A, Tatsuta M, Uehara H, et al. Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Cancer. 1995;76:750–7.PubMedCrossRef Nakaizumi A, Tatsuta M, Uehara H, et al. Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Cancer. 1995;76:750–7.PubMedCrossRef
55.
go back to reference Mikata R, Ishihara T, Tada M, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. J Gastroenterol. 2012;48:866–73.PubMedCrossRef Mikata R, Ishihara T, Tada M, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. J Gastroenterol. 2012;48:866–73.PubMedCrossRef
56.
go back to reference Kimura K, Furukawa Y, Yamasaki S, et al. A study of the usefulness of pancreatic juice cytology obtained via an endoscopic nasal pancreatic drainage (ENPD) tube. Nihon Shokakibyo Gakkai Zasshi. 2011;108:928–36 (In Japanese with English abstract).PubMed Kimura K, Furukawa Y, Yamasaki S, et al. A study of the usefulness of pancreatic juice cytology obtained via an endoscopic nasal pancreatic drainage (ENPD) tube. Nihon Shokakibyo Gakkai Zasshi. 2011;108:928–36 (In Japanese with English abstract).PubMed
57.
go back to reference Hanada K, Iiboshi T, Hirano N, et al. A social program for diagnosis of the stage 0 pancreatic cancer in a rural doctor’s association. Pancreas. 2012;41:1156. Hanada K, Iiboshi T, Hirano N, et al. A social program for diagnosis of the stage 0 pancreatic cancer in a rural doctor’s association. Pancreas. 2012;41:1156.
58.
go back to reference Hanada K, Iiboshi T. Recent advances in the early diagnosis of pancreatic cancer. Nihon Shokakibyo Gakkai Zasshi. 2013;110:2051–9 (In Japanese).PubMed Hanada K, Iiboshi T. Recent advances in the early diagnosis of pancreatic cancer. Nihon Shokakibyo Gakkai Zasshi. 2013;110:2051–9 (In Japanese).PubMed
59.
go back to reference Fukasawa M, Yoda Y, Takayama I, et al. Regional cooperation aimed at the early detection of pancreatic cancer. Kan Tan Sui. 2013;66:277–84 (In Japanese). Fukasawa M, Yoda Y, Takayama I, et al. Regional cooperation aimed at the early detection of pancreatic cancer. Kan Tan Sui. 2013;66:277–84 (In Japanese).
Metadata
Title
Diagnostic strategies for early pancreatic cancer
Authors
Keiji Hanada
Akihito Okazaki
Naomichi Hirano
Yoshihiro Izumi
Yuji Teraoka
Juri Ikemoto
Kozue Kanemitsu
Fumiaki Hino
Toshikatsu Fukuda
Shuji Yonehara
Publication date
01-02-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 2/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-014-1026-z

Other articles of this Issue 2/2015

Journal of Gastroenterology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine